The reduced rabate is for pathology and diagnostic imaging. My understanding is their main income stream (83%) comes from Gp related fees received from patients and the rest from gov subsidies and sub leasing. Thus they should be immune to a negative impact that policy shift may have. More over they mentioned the re-direction of gov funding should be benefitial for mmg.
